Esperion Therapeutics, Inc. on June 15, 2023, Jeffrey Berkowitz, J.D. notified the Board of Directors (the “Board”) of the Company of his decision to resign from the Board, effective immediately. Mr. Berkowitz's decision to resign as a director was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. In connection with Mr. Berkowitz's resignation, the Board approved the appointment of current Board member Tracy Woody as Chairperson of the Compliance Committee of the Board, effective immediately.

Following Ms. Woody's appointment, the members of the Compliance Committee are Tracy Woody (Chairperson), Seth H.Z. Fischer and Nicole Vitullo. The composition of the Compensation Committee, the Audit Committee and the Nominating and Corporate Governance Committee remains unchanged.